Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX

Add to watchlist

$15.95

+3.17

+24.9%

Market closed

Open in 3 days

-45.61%

month

-45.61%

quarter

-41.07%

year

Market Cap	1.11B
Enterprise value	N/A

P/E	-8.23
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	2.18
PEG ratio	0.01
EPS	-3.22

Revenue	N/A
EBITDA	-252.85M
Income	-240.63M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Syndax Pharmaceuticals Stock Forecast

M Q Y

Last Year

$30.6

Potential upside: 91.84%

Analysts Price target
Financials & Ratios estimates

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Profit margin
Jun 2023	0	-44.61M
Sep 2023	0	-51.14M
Dec 2023	536K	-72.47M	-13521.08%
Mar 2024	0	-72.4M

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Debt to assets
Jun 2023	431340000	31.29M	7.26%
Sep 2023	399224000	40.03M	10.03%
Dec 2023	612880000	58.68M	9.58%
Mar 2024	543028000	51.13M	9.42%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Cash Flow
Jun 2023	-35.37M	73.90M	1.32M
Sep 2023	-44.65M	40.07M	1.85M
Dec 2023	-41.34M	-16.29M	258.48M
Mar 2024	-83.54M	-99.39M	2.16M

Syndax Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Syndax Pharmaceuticals
Employees

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Employee count
Aug 2023	107
Sep 2023	107
Oct 2023	107
Nov 2023	107
Dec 2023	107
Jan 2024	107
Feb 2024	107
Mar 2024	184
Apr 2024	184
May 2024	184
Jun 2024	184
Jul 2024	184

Syndax Pharmaceuticals
Hedge Funds Holdings Q1 2023

43.17% -56.83%

of SNDX is owned by hedge funds

90 -69

hedge funds hold SNDX stock

26.23M -45.12M

shares is hold by hedge funds

SNDX hedge funds holdings changes

Syndax Pharmaceuticals
Insider Trading

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Insider trades (number of shares)
Period	Buy	Sel
Sep 2022	0	485091
Oct 2022	0	29747
Dec 2022	0	21228
Jan 2023	0	29000
Feb 2023	0	76310
Mar 2023	0	52854
Apr 2023	0	52855
May 2023	0	52855
Jun 2023	0	53432
Jul 2023	0	52855
Aug 2023	0	135855

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	9 Aug 2023	MORRISON BRIGGS director	Common Stock	52,855	$8.77	$463,538
Sale	9 Aug 2023	MORRISON BRIGGS director	Common Stock	52,855	$18.27	$965,397
Option	9 Aug 2023	MORRISON BRIGGS director	Stock Options (Right to buy)	52,855	$8.77	$463,538
Sale	2 Aug 2023	MEURY WILLIAM director director	Common Stock	83,000	$20.46	$1,697,848
Option	2 Aug 2023	MEURY WILLIAM director director	Stock Options (Right to buy)	83,000	$8.15	$676,699
Option	2 Aug 2023	MEURY WILLIAM director director	Common Stock	35,000	$7.11	$248,850
Option	2 Aug 2023	MEURY WILLIAM director director	Common Stock	48,000	$8.68	$416,400
Sale	10 Jul 2023	MORRISON BRIGGS director	Common Stock	52,855	$20.4	$1,078,083
Option	10 Jul 2023	MORRISON BRIGGS director	Stock Options (Right to buy)	52,855	$8.77	$463,538
Option	10 Jul 2023	MORRISON BRIGGS director	Common Stock	52,855	$8.77	$463,538

SNDX insider trading transactions

Syndax Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Selection of patients for combination therapy Filling date: 2 Sep 2016 Issue date: 26 Jul 2022	2 Sep 2016	26 Jul 2022
Grant	Grant Utility: Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer Filling date: 18 Mar 2016 Issue date: 10 May 2022	18 Mar 2016	10 May 2022
Application	Application SELECTION OF PATIENTS FOR COMBINATION THERAPY Filling date: 7 May 2019 Issue date: 5 Aug 2021	7 May 2019	5 Aug 2021
Application	Application COMBINATION THERAPIES Filling date: 18 May 2018 Issue date: 4 Jun 2020	18 May 2018	4 Jun 2020
Application	Application METHODS FOR THE TREATMENT OF BREAST CANCER Filling date: 15 Jan 2019 Issue date: 14 Nov 2019	15 Jan 2019	14 Nov 2019
Application	Application COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF OVARIAN CANCER Filling date: 28 Dec 2016 Issue date: 26 Sep 2019	28 Dec 2016	26 Sep 2019

SNDX patents

Syndax Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 5 Aug 2023	Q2 2023 Earnings Call Transcript

SNDX earnings call transcripts

Syndax Pharmaceuticals
Executives

Insider	Age	Since	Compensation
Dr. Briggs W. Morrison M.D. (1960) Chief Executive Officer & Director	65		$891,810
Mr. Michael A. Metzger M.B.A. (1971) Pres, Chief Operating Officer & Director	54		$856,780

Syndax Pharmaceuticals
Latest News

Monday, 9 December 2024
07:30	Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial	prnewswire.com
Saturday, 7 December 2024
18:15	Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting	prnewswire.com
Tuesday, 3 December 2024
16:05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	prnewswire.com
Wednesday, 27 November 2024
07:00	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference	prnewswire.com
Friday, 15 November 2024
18:26	US FDA approves Syndax's blood cancer drug	reuters.com
17:29	Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation	prnewswire.com
Tuesday, 12 November 2024
16:34	Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity	seekingalpha.com
07:00	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib	prnewswire.com
Tuesday, 5 November 2024
20:39	Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:10	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:01	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update	prnewswire.com
09:01	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024	prnewswire.com
09:00	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting	prnewswire.com
09:00	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting	prnewswire.com
Monday, 4 November 2024
16:01	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™	prnewswire.com
Friday, 1 November 2024
16:05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	prnewswire.com
07:00	Syndax Announces Participation in November Investor Conferences	prnewswire.com
Tuesday, 29 October 2024
07:00	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024	prnewswire.com
Friday, 4 October 2024
16:05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	prnewswire.com
Wednesday, 18 September 2024
17:15	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease	prnewswire.com
Friday, 6 September 2024
16:05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	prnewswire.com
Monday, 12 August 2024
07:00	Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia	prnewswire.com
Monday, 5 August 2024
16:05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	prnewswire.com
Friday, 2 August 2024
08:37	Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 1 August 2024
16:05	Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update	prnewswire.com
Tuesday, 30 July 2024
15:07	3 Biotech Stocks That Could Make Your Summer Unforgettable	investorplace.com
Monday, 29 July 2024
14:51	FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks	investopedia.com
07:01	Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia	prnewswire.com
Thursday, 25 July 2024
10:56	Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet	zacks.com
07:00	Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024	prnewswire.com

Ideas & Opinions

Seeking Alpha 8 Jul 2025

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Seeking Alpha 16 Jun 2024

Incyte: The Worst Has Been Avoided
Seeking Alpha 13 Oct 2023

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
Seeking Alpha 8 Sep 2023

Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
Seeking Alpha 1 Mar 2023

Syndax Pharmaceuticals: 2023 Is A Pivotal Year
Seeking Alpha 24 Jan 2023

Kura Oncology: Good Cash, Some Good Data, A Few Problems
Seeking Alpha 10 Dec 2022

Syndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain Prospect
Seeking Alpha 8 Apr 2022

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Frequently Asked Questions (FAQ)

What's the price of Syndax Pharmaceuticals stock today?

One share of Syndax Pharmaceuticals stock can currently be purchased for approximately $15.95.
When is Syndax Pharmaceuticals's next earnings date?

Unfortunately, Syndax Pharmaceuticals's (SNDX) next earnings date is currently unknown.
Does Syndax Pharmaceuticals pay dividends?

No, Syndax Pharmaceuticals does not pay dividends.
How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of 1.11B.
What is Syndax Pharmaceuticals's stock symbol?

Syndax Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SNDX".
What is Syndax Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Syndax Pharmaceuticals?

Shares of Syndax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Syndax Pharmaceuticals's key executives?
Syndax Pharmaceuticals's management team includes the following people:
- Dr. Briggs W. Morrison M.D. Chief Executive Officer & Director(age: 65, pay: $891,810)
- Mr. Michael A. Metzger M.B.A. Pres, Chief Operating Officer & Director(age: 54, pay: $856,780)
How many employees does Syndax Pharmaceuticals have?

As Jul 2024, Syndax Pharmaceuticals employs 184 workers.
When Syndax Pharmaceuticals went public?

Syndax Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 2 Mar 2016.
What is Syndax Pharmaceuticals's official website?

The official website for Syndax Pharmaceuticals is syndax.com.
Where are Syndax Pharmaceuticals's headquarters?

Syndax Pharmaceuticals is headquartered at 35 Gatehouse Drive, Waltham, MA.
How can i contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals's mailing address is 35 Gatehouse Drive, Waltham, MA and company can be reached via phone at +7 814191400.
What is Syndax Pharmaceuticals stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Syndax Pharmaceuticals in the last 12 months, the avarage price target is $30.6. The average price target represents a 91.84% change from the last price of $15.95.

Syndax Pharmaceuticals, Inc.

syndax.com

Exchange:

NASDAQ

Full time employees:

184

Industry:

Biotechnology

Sector:

Healthcare

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

+7 814191400

35 Gatehouse Drive
Waltham, MA 02451

CIK: 0001395937
ISIN: US87164F1057
CUSIP: 87164F105